Klaus Jung
#136,004
Most Influential Person Now
Researcher
Klaus Jung's AcademicInfluence.com Rankings
Klaus Jungcomputer-science Degrees
Computer Science
#6237
World Rank
#6578
Historical Rank
Computational Linguistics
#1028
World Rank
#1042
Historical Rank
Machine Learning
#1954
World Rank
#1980
Historical Rank
Artificial Intelligence
#2203
World Rank
#2241
Historical Rank
Download Badge
Computer Science
Why Is Klaus Jung Influential?
(Suggest an Edit or Addition)Klaus Jung's Published Works
Number of citations in a given year to any of this author's works
Total number of citations to an author for the works they published in a given year. This highlights publication of the most important work(s) by the author
Published Works
- Diagnostic and prognostic implications of microRNA profiling in prostate carcinoma (2009) (632)
- Betaine improves the PCR amplification of GC-rich DNA sequences. (1997) (477)
- Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy (2008) (462)
- Cell-free DNA in the blood as a solid tumor biomarker--a critical appraisal of the literature. (2010) (321)
- Robust microRNA stability in degraded RNA preparations from human tissue and cell samples. (2010) (272)
- MicroRNA profiling of clear cell renal cell cancer identifies a robust signature to define renal malignancy (2009) (242)
- Comparison of 10 serum bone turnover markers in prostate carcinoma patients with bone metastatic spread: Diagnostic and prognostic implications (2004) (233)
- Gene expression studies in prostate cancer tissue: which reference gene should be selected for normalization? (2005) (229)
- Sarcosine in urine after digital rectal examination fails as a marker in prostate cancer detection and identification of aggressive tumours. (2010) (228)
- Changes in concentration of DNA in serum and plasma during storage of blood samples. (2003) (221)
- β-Trace Protein, Cystatin C, β2-Microglobulin, and Creatinine Compared for Detecting Impaired Glomerular Filtration Rates in Children (2002) (211)
- Metastamirs: a stepping stone towards improved cancer management (2011) (182)
- Magnetic fluid hyperthermia (MFH)reduces prostate cancer growth in the orthotopic Dunning R3327 rat model (2005) (173)
- Polo‐like kinase 1 is overexpressed in prostate cancer and linked to higher tumor grades (2004) (170)
- Class I histone deacetylases 1, 2 and 3 are highly expressed in renal cell cancer (2008) (164)
- In search of suitable reference genes for gene expression studies of human renal cell carcinoma by real-time PCR (2007) (156)
- Different mRNA and protein expression of matrix metalloproteinases 2 and 9 and tissue inhibitor of metalloproteinases 1 in benign and malignant prostate tissue. (2002) (152)
- Proteomic analysis of conditioned media from the PC3, LNCaP, and 22Rv1 prostate cancer cell lines: discovery and validation of candidate prostate cancer biomarkers. (2008) (150)
- The Immune Checkpoint Regulator PD-L1 Is Highly Expressed in Aggressive Primary Prostate Cancer (2015) (150)
- Multicenter evaluation of an artificial neural network to increase the prostate cancer detection rate and reduce unnecessary biopsies. (2002) (148)
- miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcome. (2013) (147)
- CD24 expression is a significant predictor of PSA relapse and poor prognosis in low grade or organ confined prostate cancer (2004) (143)
- Interchangeability of measurements of total and free prostate-specific antigen in serum with 5 frequently used assay combinations: an update. (2006) (143)
- Comparison of eight computer programs for receiver-operating characteristic analysis. (2003) (143)
- Beta-trace protein in serum: a new marker of glomerular filtration rate in the creatinine-blind range. (1999) (134)
- Hepsin is highly over expressed in and a new candidate for a prognostic indicator in prostate cancer. (2004) (133)
- GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics (2008) (132)
- Multicenter evaluation of [-2]proprostate-specific antigen and the prostate health index for detecting prostate cancer. (2013) (128)
- Measurement of lysozyme in human body fluids: comparison of various enzyme immunoassay techniques and their diagnostic application. (1989) (126)
- Beta-trace protein, cystatin C, beta(2)-microglobulin, and creatinine compared for detecting impaired glomerular filtration rates in children. (2002) (125)
- Rapid separation of serum does not avoid artificially higher matrix metalloproteinase (MMP)-9 levels in serum versus plasma. (2007) (124)
- An optimized assay of alanine aminopeptidase activity in urine. (1980) (123)
- Molecular Cloning of the Human Kallikrein 15 Gene (KLK15) (2001) (122)
- MicroRNAs as regulators of signal transduction in urological tumors. (2011) (121)
- Molecular forms of prostate-specific antigen and human kallikrein 2 as promising tools for early diagnosis of prostate cancer. (2000) (120)
- Are cystatin C and beta 2-microglobulin better markers than serum creatinine for prediction of a normal glomerular filtration rate in pediatric subjects? (1997) (117)
- Blood specimen collection methods influence the concentration and the diagnostic validity of matrix metalloproteinase 9 in blood. (2001) (117)
- Identification and validation of suitable endogenous reference genes for gene expression studies of human bladder cancer. (2006) (112)
- The influence of prostate volume on the ratio of free to total prostate specific antigen in serum of patients with prostate carcinoma and benign prostate hyperplasia (1997) (112)
- The translational potential of microRNAs as biofluid markers of urological tumours (2016) (111)
- Evaluation of magnetic fluid hyperthermia in a standard rat model of prostate cancer. (2004) (110)
- Diagnostic, prognostic and therapeutic implications of microRNAs in urologic tumors (2010) (110)
- Measurement of Serum Levels of Macrophage Inhibitory Cytokine 1 Combined with Prostate-Specific Antigen Improves Prostate Cancer Diagnosis (2006) (109)
- Sandwich enzyme immunoassay of cystatin C in serum with commercially available antibodies. (1993) (109)
- Suitable reference genes for relative quantification of miRNA expression in prostate cancer (2010) (108)
- Relationship between semen quality and the seminal plasma components carnitine, alpha-glucosidase, fructose, citrate and granulocyte elastase in infertile men compared with a normal population. (2000) (108)
- Thermotherapy using magnetic nanoparticles combined with external radiation in an orthotopic rat model of prostate cancer (2006) (106)
- Ratio of free or complexed prostate-specific antigen (PSA) to total PSA: which ratio improves differentiation between benign prostatic hyperplasia and prostate cancer? (2000) (106)
- Increased cell-free DNA in plasma of patients with metastatic spread in prostate cancer. (2004) (103)
- A [‐2]proPSA‐based artificial neural network significantly improves differentiation between prostate cancer and benign prostatic diseases (2009) (103)
- Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer. (2013) (103)
- Complications, urinary continence, and oncologic outcome of 1000 laparoscopic transperitoneal radical prostatectomies-experience at the Charité Hospital Berlin, Campus Mitte. (2006) (100)
- Tumoural CXCL16 expression is a novel prognostic marker of longer survival times in renal cell cancer patients. (2009) (98)
- Diagnostic sensitivity of serum cystatin for impaired glomerular filtration rate (1999) (98)
- Influence of cyclosporin A on the respiration of isolated rat kidney mitochondria (1985) (97)
- Metabolic profiling reveals key metabolic features of renal cell carcinoma (2009) (96)
- Kind of sample as preanalytical determinant of matrix metalloproteinase 2 and 9 and tissue inhibitor of metalloproteinase 2 in blood. (1998) (96)
- Excretion of matrix metalloproteinases 2 and 9 in urine is associated with a high stage and grade of bladder carcinoma. (2001) (93)
- Sarcosine in prostate cancer tissue is not a differential metabolite for prostate cancer aggressiveness and biochemical progression. (2011) (93)
- Plasma osteopontin in comparison with bone markers as indicator of bone metastasis and survival outcome in patients with prostate cancer (2007) (93)
- MiR-133b Targets Antiapoptotic Genes and Enhances Death Receptor-Induced Apoptosis (2012) (92)
- MicroRNAs and cancer: current state and future perspectives in urologic oncology. (2010) (91)
- Prostate-specific antigen and other serum and urine markers in prostate cancer. (2014) (90)
- Cathepsins B, H, L and cysteine protease inhibitors in malignant prostate cell lines, primary cultured prostatic cells and prostatic tissue. (1999) (87)
- Discovery and validation of 3 novel DNA methylation markers of prostate cancer prognosis. (2007) (87)
- Reference genes for the relative quantification of microRNAs in renal cell carcinomas and their metastases. (2011) (86)
- Identification of Metastamirs as Metastasis-associated MicroRNAs in Clear Cell Renal Cell Carcinomas (2012) (85)
- Prostate-specific antigen, its molecular forms, and other kallikrein markers for detection of prostate cancer. (2002) (85)
- PSA and other tissue kallikreins for prostate cancer detection. (2007) (85)
- Urinary enzymes and low-molecular-mass proteins as indicators of diabetic nephropathy. (1988) (85)
- Inhibiting WNT and NOTCH in renal cancer stem cells and the implications for human patients (2020) (84)
- Ratio of free-to-total prostate specific antigen in serum cannot distinguish patients with prostate cancer from those with chronic inflammation of the prostate. (1998) (84)
- Piwi-interacting RNAs as novel prognostic markers in clear cell renal cell carcinomas (2015) (82)
- Reference miRNAs for miRNAome Analysis of Urothelial Carcinomas (2012) (82)
- Integrated microRNA and mRNA Signature Associated with the Transition from the Locally Confined to the Metastasized Clear Cell Renal Cell Carcinoma Exemplified by miR-146-5p (2016) (81)
- Urinary proteins and enzymes as early indicators of renal dysfunction in chronic exposure to cadmium. (1993) (80)
- Expression of the normal epithelial cell-specific 1 (NES1; KLK10) candidate tumour suppressor gene in normal and malignant testicular tissue (2001) (78)
- Detection of human kallikrein 4 in healthy and cancerous prostatic tissues by immunofluorometry and immunohistochemistry. (2002) (78)
- Matrix metalloproteinases 1 and 3, tissue inhibitor of metalloproteinase‐1 and the complex of metalloproteinase‐1/tissue inhibitor in plasma of patients with prostate cancer (1997) (78)
- Expression of the ELAV-like protein HuR in human prostate carcinoma is an indicator of disease relapse and linked to COX-2 expression. (2008) (75)
- ADAM9 expression is a significant and independent prognostic marker of PSA relapse in prostate cancer. (2008) (75)
- Periostin is up-regulated in high grade and high stage prostate cancer (2010) (75)
- The Antiapoptotic Function of miR-96 in Prostate Cancer by Inhibition of FOXO1 (2013) (75)
- Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic Acid for detection of bone metastases progression. (2007) (73)
- Identification of microRNAs in blood and urine as tumour markers for the detection of urinary bladder cancer. (2013) (72)
- The new synthetic matrix metalloproteinase inhibitor (Roche 28-2653) reduces tumor growth and prolongs survival in a prostate cancer standard rat model (2002) (72)
- Antioxidant enzymes in malignant prostate cell lines and in primary cultured prostatic cells. (1997) (71)
- Down‐regulation of the human kallikrein gene 5 (KLK5) in prostate cancer tissues (2002) (71)
- Differential expression of the human kallikrein gene 14 (KLK14) in normal and cancerous prostatic tissues (2003) (69)
- Molecular forms of prostate-specific antigen in malignant and benign prostatic tissue: biochemical and diagnostic implications. (2000) (68)
- Matrix‐metalloproteinases and their inhibitors in plasma and tumor tissue of patients with renal cell carcinoma (2000) (68)
- Identification of stanniocalcin 2 as prognostic marker in renal cell carcinoma. (2009) (68)
- Developmental changes of antioxidant enzymes in kidney and liver from rats. (1996) (67)
- Diagnostic and prognostic potential of differentially expressed miRNAs between metastatic and non-metastatic renal cell carcinoma at the time of nephrectomy. (2013) (67)
- Analytical performance and clinical validity of two free prostate-specific antigen assays compared. (1996) (67)
- Nucleic acid-based biomarkers in body fluids of patients with urologic malignancies (2014) (67)
- Increased analytical sensitivity of RT‐PCR of PSA mRNA decreases diagnostic specificity of detection of prostatic cells in blood (1997) (66)
- Artificial neural networks and prostate cancer—tools for diagnosis and management (2013) (66)
- The usefulness of serum human kallikrein 11 for discriminating between prostate cancer and benign prostatic hyperplasia. (2003) (66)
- miRNAs can predict prostate cancer biochemical relapse and are involved in tumor progression. (2011) (65)
- ADAM9 is highly expressed in renal cell cancer and is associated with tumour progression (2008) (65)
- The ratio of prostate‐specific antigen (PSA) to prostate volume (PSA density) as a parameter to improve the detection of prostate carcinoma in PSA values in the range of < 4 ng/mL (2005) (65)
- Elevated plasma osteopontin as marker for distant metastases and poor survival in patients with renal cell carcinoma (2007) (64)
- Factors influencing the ratio of free to total prostate‐specific antigen in serum (1997) (63)
- Differential expression of Kallikrein gene 5 in cancerous and normal testicular tissues. (2002) (62)
- Prostate specific antigen density to predict prostate cancer upgrading in a contemporary radical prostatectomy series: a single center experience. (2010) (62)
- The percentage of prostate‐specific antigen (PSA) isoform [–2]proPSA and the Prostate Health Index improve the diagnostic accuracy for clinically relevant prostate cancer at initial and repeat biopsy compared with total PSA and percentage free PSA in men aged ≤65 years (2016) (61)
- Comprehensive Evaluation of Prostate Specific Membrane Antigen Expression in the Vasculature of Renal Tumors: Implications for Imaging Studies and Prognostic Role (2018) (61)
- KDM5C is overexpressed in prostate cancer and is a prognostic marker for prostate-specific antigen-relapse following radical prostatectomy. (2014) (60)
- Polymerase chain reaction in the detection of micrometastases and circulating tumor cells (1996) (59)
- Integration of tissue metabolomics, transcriptomics and immunohistochemistry reveals ERG- and gleason score-specific metabolomic alterations in prostate cancer (2015) (59)
- PSA and new biomarkers within multivariate models to improve early detection of prostate cancer. (2007) (59)
- Analytical aspects regarding the measurement of metalloproteinases and their inhibitors in blood. (1997) (59)
- Quantitative analysis of kallikrein 15 gene expression in prostate tissue. (2003) (59)
- Intron retention: a common splicing event within the human kallikrein gene family. (2005) (57)
- Predictive modeling for the presence of prostate carcinoma using clinical, laboratory, and ultrasound parameters in patients with prostate‐specific antigen levels ≤ 10 ng/ml (2004) (57)
- Serum amyloid A as indicator of distant metastases but not as early tumor marker in patients with renal cell carcinoma. (2008) (57)
- Increased mRNA expression of ADAMs in renal cell carcinoma and their association with clinical outcome. (2004) (56)
- Diagnostic and prognostic potential of circulating cell-free genomic and mitochondrial DNA fragments in clear cell renal cell carcinoma patients. (2016) (56)
- Osteoprotegerin in serum as a novel marker of bone metastatic spread in prostate cancer. (2001) (55)
- Cooperative Effect of miR-141-3p and miR-145-5p in the Regulation of Targets in Clear Cell Renal Cell Carcinoma (2016) (55)
- Fatty acid binding proteins (FABPs) in prostate, bladder and kidney cancer cell lines and the use of IL-FABP as survival predictor in patients with renal cell carcinoma (2011) (55)
- Re: Roddam AW, Duffy MJ, Hamdy FC, et al. Use of prostate-specific antigen (PSA) isoforms for the detection of prostate cancer in men with a PSA Level of 2-10 ng/ml: systematic review and meta-analysis. Eur Urol 2005;48:386-99. (2005) (55)
- Claudin-1 Protein Expression is a Prognostic Marker of Patient Survival in Renal Cell Carcinomas (2008) (54)
- An artificial neural network considerably improves the diagnostic power of percent free prostate‐specific antigen in prostate cancer diagnosis: Results of a 5‐year investigation (2002) (54)
- A bibliometric evaluation of publications in urological journals among European Union countries between 2000-2005. (2007) (53)
- Plasma matrix metalloproteinase‐7 as a metastatic marker and survival predictor in patients with renal cell carcinomas (2008) (53)
- MicroRNA signature helps distinguish early from late biochemical failure in prostate cancer. (2013) (52)
- A multicenter clinical trial on the use of (-5, -7) pro prostate specific antigen. (2005) (52)
- In situ gene expression and localization of metalloproteinases MMP1, MMP2, MMP3, MMP9, and their inhibitors TIMP1 and TIMP2 in human renal cell carcinoma. (2006) (52)
- A multicenter clinical trial on the use of complexed prostate specific antigen in low prostate specific antigen concentrations. (2003) (52)
- Urinary enzymes and low molecular weight proteins as markers of tubular dysfunction. (1994) (51)
- Impact of blood sampling on the circulating matrix metalloproteinases 1, 2, 3, 7, 8, and 9. (2008) (50)
- Quantitative analysis of hippostasin/KLK11 gene expression in cancerous and noncancerous prostatic tissues. (2003) (48)
- Synthesis of [(7-Chloroquinolin-4-yl)amino]chalcones: Potential Antimalarial and Anticancer Agents (2009) (48)
- Quantitative differences in matrix metalloproteinase (MMP)-2, but not in MMP-9, tissue inhibitor of metalloproteinase (TIMP)-1 or TIMP-2, in seminal plasma of normozoospermic and azoospermic patients. (2002) (48)
- Bone turnover markers in serum and urine as diagnostic, prognostic and monitoring biomarkers of bone metastasis. (2014) (47)
- Serum osteoprotegerin and receptor activator of nuclear factor-kappa B ligand as indicators of disturbed osteoclastogenesis in patients with prostate cancer. (2003) (47)
- The membrane proteases adams and hepsin are differentially expressed in renal cell carcinoma. Are they potential tumor markers? (2004) (47)
- Punicalagin, a polyphenol from pomegranate fruit, induces growth inhibition and apoptosis in human PC-3 and LNCaP cells. (2017) (46)
- Blood sampling as critical preanalytical determinant to use circulating MMP and TIMP as surrogate markers for pathological processes (2005) (46)
- Refinements of assays for low concentrations of inulin in serum. (1990) (45)
- Words of wisdom. Re: the metabolites citrate, myo-inositol, and spermine are potential age-independent markers of prostate cancer in human expressed prostatic secretions. (2008) (45)
- Selenoprotein P Status Correlates to Cancer-Specific Mortality in Renal Cancer Patients (2012) (45)
- ADAM8 expression in prostate cancer is associated with parameters of unfavorable prognosis (2006) (45)
- Comparison of the effects of the immunosuppressive agents FK 506 and cyclosporin A on rat kidney mitochondria. (1993) (45)
- Bone turnover markers as predictive tools for skeletal complications in men with metastatic prostate cancer treated with zoledronic acid (2009) (44)
- Serum human glandular kallikrein 2 (hK2) for distinguishing stage and grade of prostate cancer (2006) (44)
- Combined determination of plasma MMP2, MMP9, and TIMP1 improves the non-invasive detection of transitional cell carcinoma of the bladder (2006) (44)
- Tissue metabolite profiling identifies differentiating and prognostic biomarkers for prostate carcinoma (2013) (44)
- Three new serum markers for prostate cancer detection within a percent free PSA‐based artificial neural network (2006) (44)
- Changed excretion of urinary proteins and enzymes by chronic exposure to lead. (1994) (43)
- A (-5, -7) proPSA based artificial neural network to detect prostate cancer. (2006) (43)
- Diagnostic significance of different urinary enzymes in patients suffering from chronic renal diseases. (1987) (43)
- Different diuresis-dependent excretions of urinary enzymes: N-acetyl-beta-D-glucosaminidase, alanine aminopeptidase, alkaline phosphatase, and gamma-glutamyltransferase. (1986) (42)
- Early urinary markers of target nephron segments as studied in cadmium toxicity. (1994) (42)
- Role of specimen collection in preanalytical variation of metalloproteinases and their inhibitors in blood. (1996) (42)
- Increased CD59 protein expression predicts a PSA relapse in patients after radical prostatectomy (2005) (41)
- Urinary Enzymes in Clinical and Experimental Medicine (1992) (41)
- β-Trace Protein Is Not Better than Cystatin C as an Indicator of Reduced Glomerular Filtration Rate (2001) (40)
- Identification of single nucleotide polymorphisms in the human kallikrein 10 (KLK10) gene and their association with prostate, breast, testicular, and ovarian cancers (2002) (39)
- Diagnostic significance of some urinary enzymes for detecting acute rejection crises in renal-transplant recipients: alanine aminopeptidase, alkaline phosphatase, gamma-glutamyltransferase, N-acetyl-beta-D-glucosaminidase, and lysozyme. (1986) (38)
- A New Algorithm for Integrated Analysis of miRNA-mRNA Interactions Based on Individual Classification Reveals Insights into Bladder Cancer (2013) (38)
- Determination of alpha1-antichymotrypsin-PSA complex in serum does not improve the differentiation between benign prostatic hyperplasia and prostate cancer compared with total PSA and percent free PSA. (1999) (38)
- Loss of SLC45A3 protein (prostein) expression in prostate cancer is associated with SLC45A3‐ERG gene rearrangement and an unfavorable clinical course (2013) (37)
- The miRNA-kallikrein axis of interaction: a new dimension in the pathogenesis of prostate cancer (2012) (37)
- Circular RNAs in Clear Cell Renal Cell Carcinoma: Their Microarray-Based Identification, Analytical Validation, and Potential Use in a Clinico-Genomic Model to Improve Prognostic Accuracy (2019) (36)
- Epithelial-mesenchymal transition-associated microRNA/mRNA signature is linked to metastasis and prognosis in clear-cell renal cell carcinoma (2016) (36)
- Diagnostic and prognostic validity of serum bone turnover markers in metastatic renal cell carcinoma. (2006) (36)
- Clinical utility of human glandular kallikrein 2 within a neural network for prostate cancer detection (2005) (36)
- GOLPH2 expression in renal cell cancer (2008) (36)
- Bone turnover markers as predictors of mortality risk in prostate cancer patients with bone metastases following treatment with zoledronic acid. (2011) (36)
- Differential expression of matrix metalloproteinases and their tissue inhibitors in human primary cultured prostatic cells and malignant prostate cell lines (2002) (36)
- Analysis of subforms of free prostate-specific antigen in serum by two-dimensional gel electrophoresis: potential to improve diagnosis of prostate cancer. (2004) (35)
- Quantification of matrix metalloproteinases and tissue inhibitors of metalloproteinase in prostatic tissue: Analytical aspects (1998) (35)
- TRPM4 protein expression in prostate cancer: a novel tissue biomarker associated with risk of biochemical recurrence following radical prostatectomy (2016) (34)
- Feedback networks between microRNAs and epigenetic modifications in urological tumors (2012) (34)
- Enzyme activities in urine: how should we express their excretion? A critical literature review. (1991) (33)
- miR‐199a‐3p and miR‐214‐3p improve the overall survival prediction of muscle‐invasive bladder cancer patients after radical cystectomy (2017) (33)
- Nucleic acid-based tissue biomarkers of urologic malignancies (2014) (32)
- The percentage of free prostate specific antigen is an age-independent tumour marker for prostate cancer: establishment of reference ranges in a large population of healthy men. (1998) (32)
- Sensitivity of HOXB13 as a Diagnostic Immunohistochemical Marker of Prostatic Origin in Prostate Cancer Metastases: Comparison to PSA, Prostein, Androgen Receptor, ERG, NKX3.1, PSAP, and PSMA (2017) (32)
- Free PSA forms in prostatic tissue and sera of prostate cancer patients: analysis by 2-DE and western blotting of immunopurified samples. (2007) (32)
- Diagnostic Value of Low-Molecular Mass Proteins in Serum for the Detection of Reduced Glomerular Filtration Rate (1987) (32)
- Age-dependent excretion of alanine aminopeptidase, alkaline phosphatase, gamma-glutamyltransferase and N-acetyl-beta-D-glucosaminidase in human urine. (1990) (32)
- mRNA expression of the five membrane‐type matrix metalloproteinases MT1–MT5 in human prostatic cell lines and their down‐regulation in human malignant prostatic tissue (2003) (32)
- An artificial neural network for five different assay systems of prostate‐specific antigen in prostate cancer diagnostics (2008) (31)
- Expression of human Kallikrein 14 (KLK14) in breast cancer is associated with higher tumour grades and positive nodal status (2006) (31)
- INCREASED PRODUCTION OF MATRIX METALLOPROTEINASE-2 IN ALVEOLAR MACROPHAGES AND REGULATION BY INTERLEUKIN-10 IN PATIENTS WITH ACUTE PULMONARY SARCOIDOSIS (2002) (31)
- Discordant total and free prostate-specific antigen (PSA) assays: does calibration with WHO reference materials diminish the problem? (2009) (31)
- Between-method differences in prostate-specific antigen assays affect prostate cancer risk prediction by nomograms. (2011) (31)
- Reduced Serum Selenoprotein P Concentrations in German Prostate Cancer Patients (2009) (31)
- Decreased RECK expression indicating proteolytic imbalance in prostate cancer is associated with higher tumor aggressiveness and risk of prostate-specific antigen relapse after radical prostatectomy. (2007) (31)
- Practical approach for determining glomerular filtration rate by single-injection inulin clearance. (1992) (31)
- Expression and regulation of prostate androgen regulated transcript-1 (PART-1) and identification of differential expression in prostatic cancer (2001) (30)
- Inhibited efficiency of kidney mitochondria isolated from rats treated with cyclosporin A. (1987) (30)
- miRNAs dysregulated in association with Gleason grade regulate extracellular matrix, cytoskeleton and androgen receptor pathways (2015) (30)
- Stability of enzymes in urine at 37°C (1983) (29)
- Overexpression of cyclooxygenase‐2 in human prostate carcinoma and prostatic intraepithelial neoplasia‐association with increased expression of polo‐like kinase‐1 (2007) (29)
- Urinary miR-183 and miR-205 do not surpass PCA3 in urine as predictive markers for prostate biopsy outcome despite their highly dysregulated expression in prostate cancer tissue (2015) (29)
- Heparin affects matrix metalloproteinases and tissue inhibitors of metalloproteinases circulating in peripheral blood. (2008) (29)
- Synthetic inhibitor of matrix metalloproteinases (batimastat) reduces prostate cancer growth in an orthotopic rat model (2000) (29)
- Dimethyl sulfoxide as additive in ready-to-use reaction mixtures for real-time polymerase chain reaction analysis with SYBR Green I dye. (2001) (29)
- Preanalytical determinants of total and free prostate-specific antigen and their ratio: blood collection and storage conditions. (1998) (28)
- Gene Promoter Methylation and Its Potential Relevance in Early Prostate Cancer Diagnosis (2010) (28)
- Antioxidant, antiangiogenic and antiproliferative activities of root methanol extract of Calliandra portoricensis in human prostate cancer cells. (2015) (28)
- Molecular forms of prostate‐specific antigen in serum with concentrations of total prostate‐specific antigen <4 μg/L: Are they useful tools for early detection and screening of prostate cancer? (2001) (28)
- Beta-trace protein is not better than cystatin C as an indicator of reduced glomerular filtration rate. (2001) (28)
- Different Stability of Free and Complexed Prostate-Specific Antigen in Serum in Relation to Specimen Handling and Storage Conditions (2000) (28)
- Comparison of the Clinical Validity of Free Prostate–Specific Antigen, Alpha–1 Antichymotrypsin–Bound Prostate–Specific Antigen and Complexed Prostate–Specific Antigen in Prostate Cancer Diagnosis (2000) (27)
- Brain-type and liver-type fatty acid-binding proteins: new tumor markers for renal cancer? (2009) (27)
- Differential Expression of a Human Kallikrein 5 (KLK5) Splice Variant in Ovarian and Prostate Cancer (2004) (27)
- Tumor M2 Pyruvate Kinase in Plasma of Patients with Urological Tumors (2001) (27)
- New 4-Maleamic Acid and 4-Maleamide Peptidyl Chalcones as Potential Multitarget Drugs for Human Prostate Cancer (2011) (27)
- Re: Hessels D, Klein Gunnewiek JMT, van Oort I, Karthaus HFM, van Leenders GJL, van Balken B, Kiemeney LA, Witjes JA, Schalken JA. DD3(PCA3)-based molecular urine analysis for the diagnosis of prostate cancer. Eur Urol 2003;44:8-16. (2004) (26)
- New markers and multivariate models for prostate cancer detection. (2009) (26)
- Comparison of p40 (ΔNp63) and p63 expression in prostate tissues – which one is the superior diagnostic marker for basal cells? (2013) (26)
- Rapid detection of elevated prostate-specific antigen levels in blood: performance of various membrane strip tests compared. (1999) (26)
- Urinary markers of malignancy. (2000) (26)
- Renal oncocytoma characterized by the defective complex I of the respiratory chain boosts the synthesis of the ROS scavenger glutathione (2017) (26)
- Improved prostate cancer detection with a human kallikrein 11 and percentage free PSA-based artificial neural network (2006) (26)
- Ischemia decreases the content of the adenine nucleotide translocator in mitochondria of rat kidney. (1991) (26)
- Lecithin: cholesterol acyltransferase activity, HDL-cholesterol and apolipoprotein A in serum of patients undergoing chronic haemodialysis. (1980) (26)
- Assay-specific artificial neural networks for five different PSA assays and populations with PSA 2–10 ng/ml in 4,480 men (2007) (25)
- Changed composition of high-density lipoprotein subclasses HDL2 and HDL3 after renal transplantation. (1988) (25)
- Down-regulation of the pro-apoptotic XIAP associated factor-1 (XAF1) during progression of clear-cell renal cancer (2009) (25)
- RECK overexpression decreases invasive potential in prostate cancer cells (2012) (25)
- Toward metrological traceability in the determination of prostate-specific antigen (PSA): calibrating Beckman Coulter Hybritech Access PSA assays to WHO standards compared with the traditional Hybritech standards (2008) (25)
- Matrix metalloproteinase-8 and tissue inhibitor of metalloproteinase-1 in serum do not reflect the analytes circulating in blood. (2008) (25)
- The androgen-regulated Calcium-Activated Nucleotidase 1 (CANT1) is commonly overexpressed in prostate cancer and is tumor-biologically relevant in vitro. (2011) (24)
- Synthesis, crystal structure and effect of indeno[1,2-b]indole derivatives on prostate cancer in vitro. Potential effect against MMP-9. (2015) (24)
- Expression of endothelial factors in prostate cancer: a possible role of caveolin-1 for tumour progression. (2011) (24)
- Benign prostatic hyperplasia-associated free prostate-specific antigen improves detection of prostate cancer in an artificial neural network. (2009) (24)
- Osteoprotegerin and Receptor Activator of Nuclear Factor-κB Ligand (RANKL) in the Serum of Healthy Adults (2002) (23)
- Comparison of two different artificial neural networks for prostate biopsy indication in two different patient populations. (2007) (23)
- Mitochondrial enzymes in human serum: comparative determinations of glutamate dehydrogenase and mitochondrial aspartate aminotransferase in healthy persons and patients with chronic liver diseases. (1985) (23)
- Circulating miRNAs in blood and urine as diagnostic and prognostic biomarkers for bladder cancer: an update in 2017. (2018) (23)
- High Expression of KLK14 in Prostatic Adenocarcinoma Is Associated with Elevated Risk of Prostate-Specific Antigen Relapse (2008) (23)
- On the pyridoxal-5'-phosphate stimulation of aspartate aminotransferase and alanine aminotransferase in serum and erythrocytes of patients undergoing chronic haemodialysis and with kidney transplants. (1981) (23)
- A Novel Predictor Tool of Biochemical Recurrence after Radical Prostatectomy Based on a Five-MicroRNA Tissue Signature (2019) (23)
- Elimination of Serum Free and Total Prostate-Specific Antigen after Radical Retropubic Prostatectomy (1997) (22)
- Differential response of oxygen radical metabolism in rat heart, liver and kidney to cyclosporine A treatment (1997) (22)
- Re: Felix K.-H. Chun, Markus Graefen, Alberto Briganti, Andrea Gallina, Julia Hopp, Michael W. Kattan, Hartwig Huland and Pierre I. Karakiewicz. Initial biopsy outcome prediction--head-to-head comparison of a logistic regression-based nomogram versus artificial neural network. Eur Urol 2007;51:1236- (2007) (22)
- Detection of PSA mRNA in blood by RT-PCR does not exclusively indicate prostatic tumor cells. (1996) (22)
- Tietz Textbook of Clinical Chemistry and Molecular Diagnostics, Fourth Edition. Carl A. Burtis, Edward R. Ashwood, and David E. Bruns, editors. St. Louis, MO: Elsevier Saunders, 2006, 2448 pp., $229.00, hardcover. ISBN 0-7216-0189-8. (2006) (22)
- Diagnostic significance of urinary enzymes in detecting acute rejection crises in renal transplant recipients depending on expression of results illustrated through the example of alanine aminopeptidase. (1985) (22)
- Repeating the measurement of prostate‐specific antigen in symptomatic men can avoid unnecessary prostatic biopsy (2003) (22)
- The Kallikrein Gene 5 Splice Variant 2 Is a New Biomarker for Breast and Ovarian Cancer (2004) (21)
- Cyclosporine A inhibits ATP net uptake of rat kidney mitochondria. (1992) (21)
- Abnormalities in the composition of serum high density lipoprotein in renal transplant recipients. (1982) (21)
- MicroRNAs as new diagnostic and prognostic biomarkers in urological tumors. (2013) (21)
- Different prostate‐specific antigen assays give different results on the same blood sample: an obstacle to recommending uniform limits for prostate biopsies (2007) (21)
- Myoglobin expression in prostate cancer is correlated to androgen receptor expression and markers of tumor hypoxia (2014) (20)
- Comparison of the diagnostic value of fatty acid synthase (FASN) with alpha‐methylacyl‐CoA racemase (AMACR) as prostatic cancer tissue marker (2010) (20)
- What kind of specimen should be selected for determining tissue inhibitor of metalloproteinase-1 (TIMP-1) in blood? (1996) (20)
- In situ gene expression of urokinase-type plasminogen activator and its receptor in transitional cell carcinoma of the human bladder. (2004) (20)
- mRNA expression profile of matrix metalloproteinases and their tissue inhibitors in malignant and non-malignant prostatic tissue. (2003) (20)
- Prostate-Specific Antigen (PSA) Screening and New Biomarkers for Prostate Cancer (PCa) (2014) (20)
- Circular RNAs: a new class of biomarkers as a rising interest in laboratory medicine (2018) (19)
- Non-hyperbolic calcium calibration curve of Fura-2: implications for the reliability of quantitative Ca2+ measurements. (1996) (19)
- Apelin and apelin receptor expression in renal cell carcinoma (2019) (19)
- Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in the serum of healthy adults. (2002) (19)
- KLK15 is a prognostic marker for progression‐free survival in patients with radical prostatectomy (2010) (19)
- ACT-PSA and complexed PSA elimination kinetics in serum after radical retropubic prostatectomy: proof of new complex forming of PSA after release into circulation. (2000) (19)
- 20-25% lower concentrations of total and free prostate-specific antigen (PSA) after calibration of PSA assays to the WHO reference materials--analysis of 1098 patients in four centers. (2009) (19)
- Culture of Human Kidney Proximal Tubular Cells – The Effect of Various Detachment Procedures on Viability and Degree of Cell Detachment (1995) (19)
- Circulating gelatinase B (MMP-9)--the impact of the preanalytical step of blood collection. (2002) (18)
- Serum or plasma: What kind of blood sample should be used to measure circulating matrix metalloproteinases and their inhibitors? (2005) (18)
- Cathepsins B, H, and L activities in urine of patients with transitional cell carcinoma of the bladder. (2002) (18)
- Serum (-5, -7) proPSA for distinguishing stage and grade of prostate cancer. (2007) (18)
- miRNA panels as biomarkers for bladder cancer. (2014) (18)
- Differential gene expression of urokinase-type plasminogen activator and its receptor in human renal cell carcinoma. (2005) (18)
- Improved determination of D-glucaric acid in urine. (1981) (18)
- Expression of cathepsins B, H, and L and their inhibitors as markers of transitional cell carcinoma of the bladder. (2004) (18)
- Prognostic relevance of proliferation markers (Ki-67, PHH3) within the cross-relation of ERG translocation and androgen receptor expression in prostate cancer (2015) (18)
- A gap between total prostate-specific antigen and the sum of free prostate-specific antigen plus alpha1-antichymotrypsin-prostate- specific antigen in patients with prostate carcinoma but not in those with benign prostate hyperplasia. (1999) (18)
- Plasma matrix metalloproteinase 9 as biomarker of prostate cancer progression in Dunning (Copenhagen) rats (2003) (17)
- Reference intervals for alpha 1-microglobulin in urine. (1992) (17)
- Urinary enzyme excretion by renal-transplant recipients in relation to interval after transplantation. (1982) (17)
- A microalbuminuria assay using bromphenol blue. (1990) (17)
- Adipophilin as prognostic biomarker in clear cell renal cell carcinoma (2017) (17)
- Receiver‐operating characteristic as a tool for evaluating the diagnostic performance of prostate‐specific antigen and its molecular forms—What has to be considered? (2001) (17)
- Effect of quinolinyl acrylate derivatives on prostate cancer in vitro and in vivo (2012) (17)
- miR-9-5p in Nephrectomy Specimens is a Potential Predictor of Primary Resistance to First-Line Treatment with Tyrosine Kinase Inhibitors in Patients with Metastatic Renal Cell Carcinoma (2018) (16)
- Current biomarkers for diagnosing of prostate cancer. (2015) (16)
- Tissue inhibitors of metalloproteinases 1 and 2 in human seminal plasma and their association with spermatozoa. (2002) (16)
- A multicenter clinical trial on the use of alpha1‐antichymotrypsin‐prostate‐specific antigen in prostate cancer diagnosis (2001) (16)
- Decreased RECK and Increased EMMPRIN Expression in Urothelial Carcinoma of the Bladder Are Associated with Tumor Aggressiveness (2011) (16)
- Germ Cell Tumors of the Gonads: A Selective Review Emphasizing Problems in Drug Resistance and Current Therapy Options (2008) (15)
- Tumor type M2 pyruvate kinase expression in metastatic renal cell carcinoma (2003) (15)
- Soluble CD44 molecules in serum of patients with prostate cancer and benign prostatic hyperplasia. (1996) (15)
- Nephron target sites in chronic exposure to lead. (1994) (15)
- Does the Prostate Health Index Depend on Tumor Volume?—A Study on 196 Patients after Radical Prostatectomy (2017) (15)
- Preanalytical pitfalls of blood sampling to measure true circulating matrix metalloproteinase 9 and tissue inhibitors of matrix metalloproteinases. (2006) (15)
- Influence of pH on the activity of enzymes in urine at 37 degrees C. (1982) (15)
- Deregulation of the COP9 signalosome-cullin-RING ubiquitin-ligase pathway: mechanisms and roles in urological cancers. (2013) (14)
- S100A8, S100A9, and the S100A8/A9 complex in circulating blood are not associated with prostate cancer risk—A re‐evaluation study (2007) (14)
- Diagnostic and prognostic value of T-cell receptor gamma alternative reading frame protein (TARP) expression in prostate cancer. (2010) (14)
- Molecular Cloning of a New Gene Which Is Differentially Expressed in Breast and Prostate Cancers (2004) (14)
- Translating molecular medicine into clinical tools: doomed to fail by neglecting basic preanalytical principles (2009) (14)
- Influence of inorganic phosphate on the activity determination of isoenzymes of alkaline phosphatase in various buffer systems. (1980) (14)
- Relation of free PSA/total PSA in serum for differentiating between patients with prostatic cancer and benign hyperplasia of the prostate: which cutoff should be used? (1998) (14)
- Laser-induced hyperthermia in rat prostate cancer: role of site of tumor implantation. (2000) (14)
- Determination of Non-α1-Antichymotrypsin-complexed Prostate-specific Antigen as an Indirect Measurement of Free Prostate-specific Antigen: Analytical Performance and Diagnostic Accuracy (2003) (14)
- Papillary Renal Cell Carcinomas Rewire Glutathione Metabolism and Are Deficient in Both Anabolic Glucose Synthesis and Oxidative Phosphorylation (2019) (13)
- Soluble CD44 variants in the serum of patients with urological malignancies. (1997) (13)
- Diuresis-dependent excretions of low-molecular mass proteins in urine: beta 2-microglobulin, lysozyme, and ribonuclease. (1988) (13)
- The prostate health index PHI predicts oncological outcome and biochemical recurrence after radical prostatectomy - analysis in 437 patients (2017) (13)
- Effect of storage temperature on the activity of superoxide dismutase, catalase, glutathione peroxidase, glutathione reductase and glutathione S-transferase in rat liver and kidney homogenates. (1993) (13)
- Reply from Authors re: Jack A. Schalken. Is Urinary Sarcosine Useful to Identify Patients With Significant Prostate Cancer? The Trials and Tribulations of Biomarker Development. Eur Urol 2010;58:19–20 (2010) (13)
- Value of prostate specific antigen density and percent free prostate specific antigen for prostate cancer prognosis. (2012) (13)
- Tietz Fundamentals of Clinical Chemistry, 6th edition. Carl A. Burtis, Edward R. Ashwood, and David E. Bruns, editors. St Louis, MO: Saunders/Elsevier, 2008, 976 pp, $96.95. ISBN 978-0-7216-3865-2. (2008) (13)
- Mitochondrial respiratory function as indicator of the ischemic injury of the rat kidney. (1985) (13)
- Particulate and free enzyme activity in urine as a result of the shedding of brush-border membranes from kidney. (1983) (12)
- Metalloproteinases and Tissue Inhibitors of Matrix‐Metalloproteinases in Plasma of Patients with Prostate Cancer and in Prostate Cancer Tissue (1999) (12)
- Instability of circular RNAs in clinical tissue samples impairs their reliable expression analysis using RT-qPCR: from the myth of their advantage as biomarkers to reality (2020) (12)
- The smartphone as a 3D input device (2012) (12)
- Inhibitory effect of cyclosporine on the respiratory efficiency of isolated human kidney mitochondria. (1987) (12)
- Matrix metalloproteinase‐2 in blood does not indicate the progression of prostate cancer (1998) (11)
- Further evidence for tubular dysfunction in insulin dependent diabetes. (1989) (11)
- Divergent effects of taurolidine as potential anti-neoplastic agent: inhibition of bladder carcinoma cells in vitro and promotion of bladder tumor in vivo. (2009) (11)
- Artificial neural networks: has the time come for their use in prostate cancer patients? (2005) (11)
- Diagnostic validity of macrophage migration inhibitory factor in serum of patients with prostate cancer: A re‐evaluation (2005) (11)
- New insights into the diagnostic accuracy of complexed and total prostate specific antigen using discordance analysis characteristics. (2006) (11)
- Internal validation of an artificial neural network for prostate biopsy outcome (2010) (11)
- Nutzung von artifiziellen neuronalen Netzwerken zur Risikoabschätzung eines Prostatakarzinoms (2003) (10)
- Tissue-Based MicroRNAs as Predictors of Biochemical Recurrence after Radical Prostatectomy: What Can We Learn from Past Studies? (2017) (10)
- Plasma miR‑15b‑5p and miR‑590‑5p for distinguishing patients with bladder cancer from healthy individuals. (2019) (10)
- Molekulare Formen des prostataspezifischen Antigens und des humanen Kallikreins 2 als mögliche Indikatoren in der Prostatakarzinomdiagnostik (2000) (10)
- Artificial neural network (ANN) velocity better identifies benign prostatic hyperplasia but not prostate cancer compared with PSA velocity (2008) (10)
- Comparison between Equimolar- and Skewed-Response Assays of Prostate Specific Antigen: Is There an Influence on the Clinical Significance When Measuring Total Serum Prostate Specific Antigen? (1996) (10)
- [Metalloproteinases (MMP-1, MMP-3) and their inhibitors (TIMP) in blood plasma of patients with prostate carcinoma]. (1998) (10)
- Risk prediction models for biochemical recurrence after radical prostatectomy using prostate-specific antigen and Gleason score (2014) (10)
- Stability of subfractions of high-density lipoproteins in stored sera. (1986) (10)
- Avoiding pitfalls in applying prediction models, as illustrated by the example of prostate cancer diagnosis. (2011) (10)
- Sex- and age-dependent reference values of alpha-1-microglobulin in urine. (1992) (10)
- PHI density prospectively improves prostate cancer detection (2021) (10)
- Plasma concentrations of metalloproteinases (MMP-1, MMP-3) and their inhibitors in patients with prostate cancer (1998) (10)
- Methods compared for determining activity of N-acetyl-beta-D-glucosaminidase in urine without pretreatment of sample: different sensitivity and species effect. (1991) (10)
- Sialidase from different sources compared for electrophoretically separating serum alkaline phosphatase fractions from liver and bone. (1989) (10)
- Importance of brain‑type fatty acid binding protein for cell-biological processes in human renal carcinoma cells. (2011) (10)
- Is serum matrix metalloproteinase 9 a useful biomarker in detection of colorectal cancer? Considering pre-analytical interference that may influence diagnostic accuracy (2008) (10)
- Loss of cadherin related family member 5 (CDHR5) expression in clear cell renal cell carcinoma is a prognostic marker of disease progression (2017) (9)
- CD146 protein in prostate cancer: revisited with two different antibodies (2008) (9)
- Sample processing and its preanalytical impact on the measurement of circulating matrix metalloproteinases (2006) (9)
- Pyridoxal phosphate activation of aminotransferases in serum of patients with kidney transplants. (1981) (9)
- N′‐Formyl‐2‐(5‐nitrothiophen‐2‐yl)benzothiazole‐6‐carbohydrazide as a potential anti‐tumour agent for prostate cancer in experimental studies (2012) (9)
- [Molecular forms of prostate-specific antigen and human kallikrein 2 as possible indicators in prostatic carcinoma diagnosis]. (2000) (9)
- Metabolic reprogramming and elevation of glutathione in chromophobe renal cell carcinomas (2019) (9)
- Strip test for the quick detection of increased concentrations of prostate-specific antigen in blood. (1996) (9)
- Multiple Forms of Alanine Aminopeptidase, Alkaline Phosphatase and γ-Glutamyltransferase in Urine of Healthy Persons, Patients Suffering from Kidney Diseases and Patients with Kidney Transplants (1984) (8)
- Discordance analysis characteristics as a new method to compare the diagnostic accuracy of tests: example of complexed versus total prostate-specific antigen. (2005) (8)
- Adenosine formation by isolated rat kidney mitochondria (1989) (8)
- Impact of Blood Sampling on Circulating Tissue Inhibitors of Metalloproteinases (2006) (8)
- Karyopherin Alpha 2 Is an Adverse Prognostic Factor in Clear‐Cell and Papillary Renal‐Cell Carcinoma (2019) (8)
- BAY 1024767 blocks androgen receptor mutants found in castration-resistant prostate cancer patients (2016) (8)
- Pre-analytical conditions for the assessment of circulating MMP-9 and TIMP-1: consideration of pitfalls (2005) (8)
- [An artificial neural network as a tool in risk evaluation of prostate cancer. Indication for biopsy with the PSA range of 2-20 microg/l]. (2003) (8)
- [New biomarkers in serum and urine for detection of prostate cancer]. (2015) (7)
- Urinary thiosulfate as failed prostate cancer biomarker – an exemplary multicenter re-evaluation study (2015) (7)
- Decreased Mitochondrial DNA Content Drives OXPHOS Dysregulation in Chromophobe Renal Cell Carcinoma (2020) (7)
- Rapid Screening of Low Molecular Mass Proteinuria: Evaluation of the First Immunochemical Test Strip for the Detection of α1-Microglobulin in Urine (1993) (7)
- Urinary osmolarity and pH and lysozyme stability. (1986) (7)
- Careful attention to blood sampling as a preanalytical determinant of circulating matrix metalloproteinase 9 to avoid misinterpretations: comment on the article by Ainiala et al. (2005) (7)
- Development of an immunoenzymometric assay for alpha 1-microglobulin and measurement of its serum concentration in normal and HIV-infected persons. (1990) (7)
- Renal cell neoplasias: reversion-inducing cysteine-rich protein with Kazal motifs discriminates tumor subtypes, while extracellular matrix metalloproteinase inducer indicates prognosis (2013) (7)
- Re: Complexed prostate specific antigen provides significant enhancement of specificity compared with total prostate specific antigen for detecting prostate cancer. (2000) (7)
- Is there an optimal prostate-specific antigen threshold for prostate biopsy? (2011) (7)
- BEDEUTUNG DER ATOPIE FUR BERUFLICH BEDINGTE IRRITATIVE UND ALLERGISCHE KONTAKTEKZEME (1999) (7)
- Harnenzyme im Experiment und in der Klinik. Bericht über ein Symposium der Humboldt-Universität Berlin und des Bezirkskrankenhauses Frankfurt/Oder in Frankfurt/Oder (DDR), 22.-25. 4. 1987 (1987) (7)
- 20–25% Lower Concentrations of Total and Free Prostate-Specific Antigen (PSA) after Calibration of PSA Assays to the WHO Reference Materials – Analysis of 1098 Patients in Four Centers (2009) (7)
- Antioxidant and antiproliferative potentials of methanol extract of Xylopia aethiopica (Dunal) A. Rich in PC-3 and LNCaP cells (2017) (7)
- Comparison of PHI and PHI Density for Prostate Cancer Detection in a Large Retrospective Caucasian Cohort (2021) (6)
- Object recognition on mobile devices (2012) (6)
- Serum Vitamin D is Not Helpful for Predicting Prostate Cancer Aggressiveness Compared with the Prostate Health Index. (2016) (6)
- Matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine: tumor-reducing effects on hormone-sensitive prostate cancer in rats (2005) (6)
- Adaptational increase of liver glutathione content during long-term application of cyclosporine A may attenuate toxic side effects. (1992) (6)
- Measurement of matrix metalloproteinases and their tissue inhibitors in serum produces doubtful results. (2008) (6)
- RE: A PROSPECTIVE STUDY TO EVALUATE THE ROLE OF COMPLEXED PROSTATE SPECIFIC ANTIGEN AND FREE/TOTAL PROSTATE SPECIFIC ANTIGEN RATIO FOR THE DIAGNOSIS OF PROSTATE CANCER (2002) (6)
- Preanalytical biases in measurement of matrix metalloproteinases and their tissue inhibitors in peripheral blood. (2007) (6)
- Circular RNAs and Their Linear Transcripts as Diagnostic and Prognostic Tissue Biomarkers in Prostate Cancer after Prostatectomy in Combination with Clinicopathological Factors (2020) (6)
- The ratio of free to total prostate‐specific antigen in serum is correlated to the prostate volume (1996) (6)
- Methodological weakness in using correlation coefficients for assessing the interchangeability of analyte data between samples collected under different sampling conditions – the example of matrix metalloproteinase 9 determined in serum and plasma samples (2010) (6)
- Creatine kinase isoenzyme BB in serum of patients undergoing chronic hemodialysis and with kidney transplant. (1979) (6)
- Diagnostic and Prognostic Potential of MicroRNA Maturation Regulators Drosha, AGO1 and AGO2 in Urothelial Carcinomas of the Bladder (2018) (6)
- The novel synthetic inhibitor of matrix metalloproteinases Ro 28-2653 induces apoptosis in Dunning tumor cells (2002) (6)
- Aktivitäten und Eigenschaften von Glutaminsynthetase und Glutamatdehydrogenase aus Nadeln von Pinus sylvestris in Abhängigkeit vom Standort (1994) (5)
- By mistakes we learn: determination of matrix metalloproteinase-8 and tissue inhibitor of matrix metalloproteinase-1 in serum yields doubtful results. (2009) (5)
- Advances in Biomarkers for PCa Diagnostics and Prognostics—A Way towards Personalized Medicine (2017) (5)
- Physiological Factors Influencing Enzyme Excretion (1992) (5)
- Electrophoretic subforms of free prostate-specific antigen in serum as promising diagnostic tool in prostate cancer diagnostics. (2007) (5)
- Rapid screening of PSA: evaluation of an immunochemical membrane strip test. (1995) (5)
- Metabolic Rates of 4-Hydroxynonenal in Tubular and Mesangial Cells of the Kidney (1999) (5)
- Thiosulfate in urine: new hope or new failure of a biomarker for prostate cancer? (2013) (5)
- Evaluation of methods for determining N-acetyl-beta-D-glucosaminidase in urine of rats without purification of urine samples. (1991) (5)
- New Insights Into the Mechanism of COP9 Signalosome-Cullin-RING Ubiquitin-Ligase Pathway Deregulation in Urological Cancers. (2016) (5)
- Blood sampling affects circulating TIMP‐1 concentration, a useful biomarker in estimating liver fibrosis stages (2008) (5)
- Single-injection inulin clearance using only one blood sample as a suitable procedure to measure glomerular filtration rate. (1991) (5)
- More about determination of N-acetyl-beta-D-glucosaminidase activity in urine without pretreatment of samples. (1988) (5)
- Häufigkeit und Ursachen der fetalen und neonatalen Makrosomie (1982) (5)
- b-Trace Protein in Serum: A New Marker of Glomerular Filtration Rate in the Creatinine-Blind Range, Friedrich (1999) (5)
- [A new kinetic method for measuring beta-N-acetylglucosaminidase activity in urine]. (1991) (5)
- Re: Scott A. Tomlins, John R. Day, Robert J. Lonigro, et al. Urine TMPRSS2:ERG Plus PCA3 for Individualized Prostate Cancer Risk Assessment. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2015.04.039. (2015) (4)
- Glutathione S‐transferase‐pi protein expression in prostate cancer–not always a useful diagnostic tool (2015) (4)
- Effect of Starvation on Antioxidant Enzymes and Respiratory Mitochondrial Functions in Kidney and Liver from Rats (1997) (4)
- Ratio of alpha 1-antichymotrypsin--prostate specific antigen to total prostate specific antigen in prostate cancer diagnosis. (2000) (4)
- Stability of enzymes in urine at 37 degrees C. (1983) (4)
- Isoforms of prostate‐specific antigen in serum: A result of the glycosylation process in dysplastic prostatic cells? (1996) (4)
- Enhanced inhibitory effect of the matrix metalloproteinase inhibitor Ro 28-2653 in combination with estramustine and etoposide on the prostate carcinoma in the rat Dunning orthotopic tumor model (2006) (4)
- Endocytosis-Mediated Replenishment of Amino Acids Favors Cancer Cell Proliferation and Survival in Chromophobe Renal Cell Carcinoma (2020) (4)
- The prostate health index PHI predicts oncological outcome and biochemical recurrence after radical prostatectomy - analysis in 437 patients. (2017) (4)
- Deponiesickerwässer: Bestimmung zytotoxischer Wirkungen mit dem Pollenschlauchwachstumstest (1997) (4)
- What are the Criteria to Introduce New Methods for Determination of Urinary N-Acetyl-β-D-Glucosaminidase Activity? (1993) (4)
- Multiple forms of N-acetyl-beta-D-glucosaminidase of human urine: isolation, properties and the development of a practical approach of differentiation. (1991) (4)
- Increased serum gamma-glutamyltransferase activity in renal transplant recipients: liver damage or microsomal enzyme induction? (1984) (4)
- Der Einfluß von Pyridoxal-5’-phosphat auf das Temperaturverhalten der Aspartataminotransferase-Isoenzyme (1975) (4)
- [Urinary enzymes in research and in clinical medicine. Report on a symposium of the Humboldt-Universität Berlin and the Bezirkskrankenhaus Frankfurt/Oder in Frankfurt/Oder, 22-25 April 1987]. (1987) (4)
- Sportanthropologie : Fragestellungen, Methoden und Ergebnisse am Beispiel der Laufdisziplinen und des alpinen Skirennsports (1998) (4)
- Effects of preservation solutions on cortical and medullary mitochondria of rat kidney. (1995) (4)
- A practical new assay for determining N-acetyl-beta-D-glucosaminidase activity in urine. (1991) (4)
- COMMENT ON: CAN PROSTATE SPECIFIC ANTIGEN DERIVATIVES REDUCE THE FREQUENCYOF UNNECESSARY PROSTATE BIOPSIES BY PRESTIGIACOMO ET AL (1997) (3)
- GOLPH 2 expression in renal cell cancer (2015) (3)
- Cathepsins B, H, L and cysteine proteinase inhibitors in renal cell carcinoma: no evidence for dysregulated proteolytic balance (1998) (3)
- Re: Editorial: can prostate specific antigen derivatives reduce the frequency of unnecessary prostate biopsies? (1997) (3)
- Renal fibronectin excretion as a marker for renal environmental toxins. (1993) (3)
- Circulating matrix metalloproteinase-7: an early or metastatic marker for renal cell carcinoma? (2008) (3)
- Serum testosterone improves the accuracy of Prostate Health Index for the detection of prostate cancer. (2014) (3)
- Matrix metalloproteinases do not properly work as peripheral blood biomarkers without taking into account the preanalytical impact of blood sampling. (2008) (3)
- Ischemia-induced alterations of rat kidney mitochondria. (1990) (3)
- Synthesis, Antiproliferative, and Antiangiogenic Activities of Benzochromene and Benzoquinoline Derivatives on Prostate Cancer in vitro (2017) (3)
- Tumor-M2-Pyruvatkinase beim Nierenzellkarzinom Untersuchungen im Plasma von Patienten (2000) (3)
- Anomalous Flotation of Separator Gel : Density or Viscosity ? (3)
- Consideration of preanalytical conditions to use circulating matrix metalloproteinases as diagnostic markers. (2005) (3)
- Determination of purine compounds by ion-pair microbore high-performance liquid chromatography: application to ischemic rat kidney mitochondria. (1990) (3)
- [Tumor M2 pyruvate kinase in renal cell carcinoma. Studies of plasma in patients]. (2000) (3)
- Urinary Enzymes in Renal, Renal-Associated and Urological Disorders (1992) (3)
- Different susceptibility of cortical and medullary rat kidney mitochondria to ischemic injury. (1988) (3)
- Consideration of preanalytical impact of blood sampling on measurement of matrix metalloproteinases and their inhibitors as precondition to evaluate their relationship to clinical data (2009) (3)
- DIE BEDEUTUNG DES ALASTAT-ALABLOT IMMUNOBLOT FUR DIE DIAGNOSE VON INSEKTENGIFTALLERGIEN (1999) (3)
- Reply to Amitha K Hewavitharana’s Letter to the Editor re: Florian Jentzmik, Carsten Stephan, Kurt Miller, et al. Sarcosine in Urine After Digital Examination Fails as a Marker in Prostate Cancer Detection and Identification of Aggressive Tumours. Eur Urol 2010;58:12–8 (2010) (3)
- Soluble CD44 variants in serum of patients with prostate cancer and other urological malignancies (1996) (3)
- The discriminative ability of Prostate Health Index to detect prostate cancer is enhanced in combination with miR-222-3p. (2020) (3)
- [MicroRNA in uro-oncology : New hope for the diagnosis and treatment of tumors?]. (2009) (3)
- CD103+ Tissue Resident T-Lymphocytes Accumulate in Lung Metastases and Are Correlated with Poor Prognosis in ccRCC (2022) (3)
- Freies prostataspezifisches Antigen im Serum: eine Meßgröße zur Diskrimination zwischen Patienten mit Prostatakarzinom und benigner Prostatahyperplasie (1996) (2)
- [Quantifying gene expression in prostate carcinoma. Which endogenous reference genes are suitable?]. (2007) (2)
- 31P-NMR spectroscopy and ultrastructural studies on nephrotoxicity of cyclosporine A. (1987) (2)
- Analytical Aspects regarding the Measurement of Metalloproteinases (1999) (2)
- Serum Macrophage Migration Inhibitory Factor Is Not Elevated in Patients with Prostate Cancer (2004) (2)
- Serum samples are inappropriate for use in measuring circulating matrix metalloproteinases: comment on the article by Young-Min et al. (2008) (2)
- Measurement Conditions for Flow Cytometry Analyses of Cell Lines from Urological Carcinomas (2010) (2)
- Blood sampling and the measurement of circulating matrix metalloproteinase-8. (2008) (2)
- Das Verhältnis freies PSA/Gesamt-PSA - eine Kenngröße zur Differenzierung zwischen Patienten mit Prostatakarzinom und benigner Prostatahyperplasie: Welcher Diskriminationspunkt sollte gewählt werden? (1997) (2)
- Prostataspezifisches Antigen (PSA): Einfluß des freien und gebundenen Anteils auf die klinische Aussagekraft als Tümormarker (1995) (2)
- Limited utility of qPCR-based detection of tumor-specific circulating mRNAs in whole blood from clear cell renal cell carcinoma patients (2020) (2)
- Predictive Modeling for the Presence of Prostate Carcinoma Using Clinical, Laboratory, and Ultrasound Parameters in Patients with Prostate-Specific Antigen Levels ≤ 10 ng/mL [2] (multiple letters) (2004) (2)
- Urinary Enzymes in Kidney Transplantation (1992) (2)
- Zum Einfluß von schwerem Wasser auf die Vitalität vonSaccharomyces cerevisiae (2004) (2)
- Prognostic Role of Survivin and Macrophage Infiltration Quantified on Protein and mRNA Level in Molecular Subtypes Determined by RT-qPCR of KRT5, KRT20, and ERBB2 in Muscle-Invasive Bladder Cancer Treated by Adjuvant Chemotherapy (2020) (2)
- [New biomarkers and application of multivariate models for detection of prostate cancer]. (2009) (2)
- Urinary enzyme excretion after donor nephrectomy--how should we express and compare excretion rates of the remaining kidney after donor nephrectomy? (1990) (2)
- Assay-dependent abnormalities in measurements of prostate-specific antigen in serum: an occasional occurrence, but of clinical significance (2012) (2)
- 208Evaluation of magnetic fluid hyperthermia (MFH) combined with external radiation in an orthotopic rat model of prostate cancer (2005) (2)
- Lymphatic micrometastases predict biochemical recurrence in patients undergoing radical prostatectomy and pelvic lymph node dissection for prostate cancer (2018) (2)
- Ein farbtest zur bestimmung der glutamatdehydrogenase-aktivität im serum (1972) (2)
- 105 HIGH EXPRESSION LEVELS OF THE HUMAN KALLIKREIN-LIKE PEPTIDASES KLK14 AND KLK 15 IN PROSTATIC ADENOCARCINOMA ARE ASSOCIATED WITH ELEVATED RISK OF PROSTATE-SPECIFIC ANTIGEN RELAPSE (2007) (1)
- Erfolgswirksamkeit von Visionen — Ergebnisse einer qualitativen empirischen Untersuchung (1999) (1)
- Inhibiting WNT and NOTCH in renal cancer stem cells and the implications for human patients (2020) (1)
- Influence of Mg2+ ions on the activity measurement of isoenzymes of alkaline phosphatase. (1979) (1)
- Die Brandgans(Tadorna tadorna) Brutvogel und Überwinterer bei Salzgitter (2005) (1)
- Electronic-Shopping — Die Zukunft des Versandhandels? Eine vergleichende Betrachtung empirischer Untersuchungen von 1997 und 2000 (2001) (1)
- 805 PSA-VELOCITY AND ARTIFICIAL NEURAL NETWORK (ANN)-VELOCITY TO DIFFERENTIATE PROSTATE CANCER FROM BENIGN PROSTATIC DISEASE (2007) (1)
- Proteinmikrobestimmung an einem Protein‐Träger‐Komplex mit Hilfe der Isotopenverdünnungsanalyse von Stickstoff (1979) (1)
- Vergleichende Einschätzung der diagnostischen Aussagekraft der Kenngrößen freies PSA, Alpha1-Antichymotrypsin-PSA und komplexiertes PSA in der Diagnostik des Prostatakarzinoms (2001) (1)
- 773 Piwi-interacting RNAs as novel prognostic markers in clear cell renal cell carcinomas (2015) (1)
- [Human kallikreins as tumor markers. Validation of potential marker of prostate cancer in serum and tissue]. (2007) (1)
- 859 Parallel measurement of urinary PCA3 and TMPRSS2:ERG with serum [−2]proPSA based Phi for prostate cancer detection (2013) (1)
- Papillary renal cell carcinomas rewire glutathione metabolism and are deficient in anabolic glucose synthesis (2019) (1)
- Correspondence re: C. F. M. Sier et al., Enhanced urinary gelatinase activities (matrix metalloproteinases 2 and 9) are associated with early-stage bladder carcinoma: a comparison with clinically used tumor markers. Clin. Cancer Res., 6: 2333-2340, 2000. (2001) (1)
- Different effects of cyclosporine and tacrolimus on the activation of mesangial metalloproteinases and their inhibitors. (1999) (1)
- The value of digital rectal examination in clinical practice (2018) (1)
- Teile dieser Arbeit wurden in den folgenden Arbeiten publiziert (2007) (1)
- Re: Elevated level of circulating matrix metalloproteinase-9 in patients with lung cancer (Respir Med 2001; 95: 1-4). (2002) (1)
- The adenine nucleotide catabolism in nonphosphorylating mitochondria of different tissues. (1989) (1)
- Determination of non-alpha1-antichymotrypsin-complexed prostate-specific antigen as an indirect measurement of free prostate-specific antigen: analytical performance and diagnostic accuracy. (2003) (1)
- COMPARISON OF THE “GOLD” STANDARD ACCESS ® PSA (HYBRITECH) ASSAY WITH THE NEW BECKMAN COULTER WHO- STANDARDIZED CALIBRATED ACCESS ® PSA ASSAYS (2008) (1)
- Periodate-oxidized ATP stimulates the permeability transition of rat liver mitochondria. (1998) (1)
- Plasma but not serum should be used for determining tissue inhibitor of metalloproteinase in blood. (1997) (1)
- Zum Einfluß der Temperatur auf Enzymaktivitätsbestimmungen im Serum: Glutamatdehydrogenase (1974) (1)
- Mechanisms accounting for changes of adenine nucleotide content in mitochondria at ischemia. (1991) (1)
- THE FIRST ARTIFICIAL NEURAL NETWORK FOR FIVE DIFFERENT PSA-ASSAYS IN PROSTATE CANCER DIAGNOSTICS (2008) (1)
- A review of expression profiling of circulating microRNAs in men with prostate cancer (2013) (1)
- Misinterpretation of quantitative RT-PCR results: A comment on the article by Ohashi et al. "RNA degradation in human breast tissue after surgical removal: a time course study", Exp. Mol. Pathol. 77 (2004) 98-103. (2005) (1)
- Abstract 1415: Prostate cancer: An integrated evaluation of metabolomics, transcriptomics, and proteomics expression data (2014) (1)
- Kind of Sample as Preanalytical Determinant of Matrix Metalloproteinases 2 and 9 and Tissue Inhibitor of Metalloproteinase 2 in Blood, Matrix metalloproteinases and tissue inhibitors (1998) (1)
- Tietz’s Applied Laboratory Medicine, 2nd ed. Mitchell G. Scott, Ann M. Gronowski, and Charles S. Eby, eds. Hoboken, NJ: Wiley-Interscience, a John Wiley & Sons, Inc. Publication, 2007, 679 pp., $69.95, paperback. ISBN 978-0-471-71457-6. (2007) (1)
- Re: A molecular correlate to the Gleason grading system for prostate adenocarcinoma. (2007) (1)
- Elimination of Serum Complexed Prostate-Specific Antigen after Radical Retropubic Prostatectomy (2000) (1)
- Editorial comment on: diagnostic value of free prostate-specific antigen among men with a prostate-specific antigen level of <3.0 microg per liter. (2008) (1)
- Consideration of important preanalytical conditions for the assessment of circulating matrix metalloproteinase-9. (2005) (1)
- Soluble CD44 Molecules in Serum of Patients with Cancer and Benign Prostatic Hyperplasia Prostate (1996) (1)
- Bedeutung der Surfactant-Proteine B und D in der Differentialdiagnostik der akuten Dyspnoe (2010) (1)
- 296 AN AUTOMATED ASSAY FOR – 2PROPSA SIGNIFICANTLY IMPROVES PROSTATE CANCER (PCA) DETECTION IN ARTIFICIAL NEURAL NETWORK OR LOGISTIC REGRESSION MODELS AND ENHANCES DIFERENTIATION OF AGGRESSIVE PCA (2009) (1)
- Stand und Entwicklung der strategischen Logistikplanung — Ergebnisse empirischer Untersuchungen von 1999 und 2000 im Vergleich (2001) (1)
- Logistik der Zukunft: Echter Wertbeitrag für das Unternehmen (2018) (0)
- Der Tumorsuppressor RECK im Prostatakarzinom (2007) (0)
- Die Bedeutung des Immunblotting für die Diagnose von Insektengiftallergien (2002) (0)
- Diagnostik von Nierenschäden bein Schwermetallexpositionen (1996) (0)
- Title: Golph2 Expression in Renal Cell Cancer (2008) (0)
- [Rational gel filtration method for the processing of urine for enzyme activity determinations]. (1985) (0)
- Trast Media Interfere with Gel Barrier Formation in Plasma and Serum Separators Tubes. Clin (2008) (0)
- Wein – Genuss und Gesundheit (2012) (0)
- Oncology: Prostate/Testis/Penis/Urethra A MULTICENTER CLINICAL TRIAL ON THE USE OF (-5, -7) PRO PROSTATE SPECIFIC ANTIGEN (2005) (0)
- UrinaryEnzymes : N-Acetyl-f 3-D-glucosaminidase , AlanineAminopeptidase , AlkalinePhosphatase , and y-Glutamyltransferase (2004) (0)
- Influence of lyophilization on the inhibition of alkaline phosphatase activity by inorganic phosphate. (1981) (0)
- [Determination of kallikrein in gel-filtered urine using the chromogenic substrate D-valyl-L-leucyl-L-arginyl-4-nitroanilide]. (1991) (0)
- Effect of immunosuppressive treatment on aminotransferase activities in serum of renal-transplant recipients. (1988) (0)
- [Oxidative and respiratory properties of isolated human kidney mitochondria]. (1987) (0)
- [Tumor suppressor RECK in prostate carcinoma. Decreased RECK expression as indicator of proteolytic imbalance]. (2007) (0)
- [Lipid parameters in the perfusate of dog kidneys following hypothermic pulsatile preservation]. (1983) (0)
- [Lipid composition of microsomes and mitochondria of the rat kidney cortex]. (1985) (0)
- The Prostate ThreeNewSerumMarkers for ProstateCancer DetectionWithin a Percent Free PSA-Based ArtificialNeuralNetwork (2005) (0)
- Lecithin:cholesterol acyltransferase activity and HDL composition in serum of patients with kidney transplants. (1983) (0)
- 176 THE NEW AUTOMATED BPHA (BPSA) ASSAY IMPROVES DETECTION OF PROSTATE CANCER IN AN ARTIFICIAL NEURAL NETWORK (2009) (0)
- 20 Geräusche/Töne bei der körperlichen Untersuchung (2016) (0)
- 7 Nieren/Ableitende Harnwege (2016) (0)
- „Lizenz Sport und Diabetes“: Erfahrungsbericht dreijähriger Modularbeit der Universitätsausbildung – Sporttherapie (2006) (0)
- Die Bedeutung von Adhäsionsmolekülen für die atopische Entzündung (2000) (0)
- Preanalytical Interferences Compromise the Clinical Validity of Matrix Metalloproteinase 1 as Marker of Colorectal Cancer (2011) (0)
- Piwi-interacting RNAs as novel prognostic markers in clear cell renal cell carcinomas (2015) (0)
- [Characteristic respiratory magnitude of isolated mitochondria of the rat kidney cortex in relation to measurement conditions]. (1985) (0)
- 139 Overexpression of Drosha, Argonaute 1 and 2 in patients with urothelial carcinomas (2014) (0)
- Null Results in Brief Serum Macrophage Migration Inhibitory Factor Is Not Elevated in Patients with Prostate Cancer (2004) (0)
- Vitamin D Metabolites in Nonmetastatic High-Risk Prostate Cancer Patients with and without Zoledronic Acid Treatment after Prostatectomy (2022) (0)
- Metalloproteinasen (MMP-1, MMP-3) und ihre Inhibitoren (TIMP) im Blutplasma bei Patienten mit Prostatakarzinom (1998) (0)
- [Functional properties of isolated kidney mitochondria of rats in food deprivation]. (1989) (0)
- [New serum markers in prostate carcinoma and their application to artificial neural networks]. (2007) (0)
- Affinity chromatography of urinary brush-border enzymes on concanavalin-Sepharose. (1984) (0)
- [Determination of the enzyme activity of the blood serum in the diagnosis of liver diseases in patients following a kidney transplant]. (1986) (0)
- [New serum markers of bone metastasis in prostate carcinoma]. (2007) (0)
- Simplex optimized determination of d glucaric acid in urine and its clinical application (1981) (0)
- DYS - REGULATIONOF EXTRACELLULAR MATRIX PROTEINS TURNOVER BY HIGH GLUCOSE CONCENTRATIONSIN CULTURED HUMAN GLOMERULAR MESANGIAL CELLS (1999) (0)
- Elevated level of circulatingmatrix metalloproteinase-9 inpatientswith lung cancer ( Respir Med 2001 ; 95 : 1 ^ 4 ) : a reply (0)
- MATRIX METALLOPROTEINASES (MMP) AND TISSUE INHIBITORS OF MMP (TIMP) IN RENAL CELL CARCINOMA (1999) (0)
- Pyridoxal-5' -phosphate stimulation of aminotransferase activities in serum of hemodialysis patients and renal-transplant recipients. (1996) (0)
- 472 EPIGENETICALLY REPRESSED MIRNAS AS PREDICTORS OF TUMOR RECURRENCE IN CLEAR CELL RENAL CELL CARCINOMA PATIENTS FOLLOWING RADICAL NEPHRECTOMY (2013) (0)
- 1982 HEAD TO HEAD COMPARISON OF THE ERSPC RISK CALCULATOR AND ANN PROSTATACLASS IN 4685 PATIENTS FOR PROSTATE CANCER RISK ON BIOPSY (2010) (0)
- [Urine enzymes and low molecular weight proteins as indicators of diabetic nephropathy]. (1989) (0)
- Logistische Zukunftsforschung aus Sicht eines Automobilherstellers — am Beispiel der Wachstumsregion Südamerika (2001) (0)
- [Evaluation of methods for the analysis of low insulin concentrations in serum]. (1991) (0)
- An OptimizedAssayof AlanineAminopeptidaseActivityin Urine (2004) (0)
- [The low molecular weight proteins ribonuclease, beta 2 microglobulin and lysozyme in the serum and urine of patients with chronic kidney diseases]. (1988) (0)
- Anlage zum sortieren von flaschen (1979) (0)
- The way of prostate cancer diagnostics (2016) (0)
- COMMENT ON: FREE AND COMPLEXED PROSTATE SPECIFIC ANTIGEN IN THE DIFFERENTIATION OF BENIGN PROSTATIC HYPERPLASIA AND PROSTATE CANCER : STUDIES IN SERUM AND PLASMA SAMPLES. AUTHORS' REPLY (1999) (0)
- [Lipid changes following ischemic damage to the kidney in the rat]. (1983) (0)
- 4 Herz-Kreislauf/Gefäße (2016) (0)
- Untersuchungen zur Auswirkung von Ausdauerübungen im Sportunterricht auf die körperliche Leistungsfähigkeit von Gymnasiasten (1984) (0)
- [Urine enzyme activities in chronic renal diseases]. (1985) (0)
- Is NF-κB predictive of biochemical recurrence in positive-margin prostate cancer? (2005) (0)
- [Determination of free fatty acids with a diphenylcarbazide color reagent]. (1983) (0)
- Lipoproteins in serum of patients during long-term haemodialysis and after kidney transplantation: behaviour of HDL- and LDL-cholesterol and of apoproteins A and B. (1980) (0)
- 802 DIFFERENT PSA ASSAYS GIVE DIFFERENT RESULTS ON THE SAME BLOOD SAMPLE -A SERIOUS OBSTACLE TO RECOMMEND UNIFORM LIMITS FOR PROSTATE BIOPSIES (2007) (0)
- Criteria for Detection of Heterozygous indIviduals with Lactate Dehydrogenase Subunit Deficiencies (2004) (0)
- Über die Beeinflussung der experimentellen eitrigen Bronchitis durch Inhalation von Mineralwässern (1937) (0)
- Osteocalcin und die Knochenfraktion der alkalischen Phosphatase im Serum nierentransplantierter Patienten (1992) (0)
- Stand und Entwicklung der strategischen Logistikplanung - Ergebnisse einer empirischen Untersuchung (2000) (0)
- Methods in molecular biology: minor errors in primer citations with major consequences: how can we minimize these mistakes? (2000) (0)
- MP85-18 CIRCULATING FREE GENOMIC AND MITOCHONDRIAL DNA FRAGMENTS AND THEIR DIAGNOSTIC AND PROGNOSTIC POTENTIAL IN CLEAR CELL RENAL CELL CARCINOMA PATIENTS (2016) (0)
- [Urinary enzyme excretion in kidney transplant patients]. (1983) (0)
- Endspurt Heilpraktikerprüfung: Tabellarisches Kurzkompendium (2016) (0)
- Differentially expressed genes in prostate cancer — identification of CD24 as a new prognostic marker (2004) (0)
- Re: Al-Azab R, Toi A, Lockwood G, et al. Prostate volume is strongest predictor of cancer diagnosis at transrectal ultrasound-guided prostate biopsy with prostate-specific antigen values between 2.0 and 9.0 ng/mL (Urology 69:103-107, 2007). (2008) (0)
- Reply (2008) (0)
- 1289 MIR-96 REGULATES APOPTOSIS IN PROSTATE CANCER VIA INHIBITION OF FOXO1 (2011) (0)
- Sample/reagent volume ratIo Table 1. Effect of Sample/Reagent Volume Ratio on NAG Activity Measured by Various Methods (1988) (0)
- 5 Leber, Galle, Pankreas (2016) (0)
- Zum 65. Geburtstag von Professor Hans Faust (1993) (0)
- Ein kontinuierlicher Test zur Bestimmung der N-Acetyl-ß-D-glucosaminidase-Aktivität im Harn mit dem Substrat 3,3'-Dichlorphenol-sulfonphthaleinyl-N-acetyl-ß-D-glucosaminid: ein Vergleich mit anderen Methoden ohne Probenvorbereitung (1991) (0)
- [Reply to: PSA screening : Possible uses and harm by N. Keller, M. Jenny, G. Gigerenzer, R. Ablin]. (2018) (0)
- Table 1. Correlation, mean, range, and mean differences of pairs of results for samples measured on the Variant Express and Diamat. (1999) (0)
- AN ARTIFICIAL NEURAL NETWORK FOR FIVE DIFFERENT PSAASSAYS IN PROSTATE CANCER DIAGNOSTICS (2008) (0)
- 350 POSTER Chass I histone deacetylase isoforms in prostate cancer: expression patterns in vivo and functional implications in vitro (2006) (0)
- Apelin and apelin receptor expression in renal cell carcinoma (2019) (0)
- Erratum to: Strahlentherapie und Onkologie, Volume 186 (No. 1) (2010) (0)
- Verhalten von Laktat, Atem- und Blutgasen an der aeroben und anaeroben Schwelle (1985) (0)
- Renal cell neoplasias: reversion-inducing cysteine-rich protein with Kazal motifs discriminates tumor subtypes, while extracellular matrix metalloproteinase inducer indicates prognosis (2013) (0)
- 50 Jahre Anaphylaxie (2019) (0)
- Letter to the Editor Correspondence re: C. F. M. Sieret al., Enhanced Urinary Gelatinase Activities (Matrix Metalloproteinases 2 and 9) Are Associated with Early-Stage Bladder Carcinoma: A Comparison with Clinically Used Tumor (2001) (0)
- Professor Lothar Jäger zu seinem 80. Geburtstag (2014) (0)
- DIAGNOSTIC VALIDITY OF VARIOUS MEMBRANE STRIP TESTS FOR RAPID DETECTION OF EVALUATED PSA-LEVEL (1999) (0)
- 236. Chronische calcifizierende und nicht calcifizierende Pankreatitis: Gibt es Unterschiede in der Verlaufsform? (1987) (0)
- Interaktive Tools für die Lehre der Statistischen Bioinformatik (2017) (0)
- Die Rolle des Wassers in biologischen Systemen (1970) (0)
- MP63-05 SERUM TESTOSTERONE IMPROVES THE ACCURACY OF PROSTATE HEALTH INDEX FOR THE DETECTION OF PROSTATE CANCER (2014) (0)
- 170 20-25% LOWER PSA VALUES WITH PSA TEST STANDARDIZATION TO THE WHO REFERENCE MATERIAL: SUMMARY OF 4 STUDIES IN 1100 PATIENTS (2009) (0)
- Der Wertbeitrag der Logistik – von der Kostensenkung zur Marktpositionierung (2012) (0)
- Comment on: Application of Artificial Intelligence to the Management of Urological Cancer. Authors' reply (2008) (0)
- Gegendarstellung zu: PSA‑Screening (2018) (0)
- Abstract 3224: Metabolite profiling as tool for the identification of differentiating and prognostic markers of prostate carcinoma. (2013) (0)
- Re: Application of artificial intelligence to the management of urological cancer. M. F. Abbod, J. W. Catto, D. A. Linkens and F. C. Hamdy J Urol 2007; 178: 1150-1156. (2008) (0)
- STUDY ON SECRETION OF MATRIX METALLOPRO-TEINSES AND THEIR BIOLOGICAL TISSUE INHIBITORS BY CULTURED HUMAN GLOMERULAR MESANGIAL CELLS (2000) (0)
- 6 Endokrinologie/Stoffwechsel (2016) (0)
- Strongly Increased International Normalized Ratio with Recombinant Neoplastin R Compared with Tissue Extract Neoplastin Plus in Patients Initiating Oral Anticoagulant Therapy: Implications for Anticoagulation Dosage To the Editor: High-accuracy determination of the international normalized ratio (2008) (0)
- Humane Kallikreine als Tumormarker (2007) (0)
- Vascular expression of prostate-specific membrane antigen in renal tumors: Diagnostic and prognostic role (2018) (0)
- Einfluß von Probengewinnung und Lagerungsbedingungen auf die Stabilität des totalen und freien prostata-spezifischen Antigens. Influence of Sample Collection and Storage Conditions on the Stability of Total and Free Prostate-specific Antigen (1998) (0)
- Präanalytische und analytische Aspekte bei der Bestimmung von Metalloproteinasen und ihren Inhibitoren im Blut (1997) (0)
- 20-25% Lower Psa Values With Psa Test Standardization To the Who Reference Material: Summary of 4 Studies in 1100 Patients (2009) (0)
- Klinische Bedeutung unterschiedlicher KRAS-Mutationen im Rektumkarzinom (2013) (0)
- 745 PROFILING OF MICRORNAS IN PROSTATE CANCER IDENTIFIES DISTINCT CHANGES IN MICRORNA EXPRESSION PATTERNS (2010) (0)
- Use of microRNA signature to distinguish early from late biochemical failure in prostate cancer. (2013) (0)
- 19 Anamnese und Differenzialdiagnose (2016) (0)
- Can complexed PSA improved the prostate cancer detection rate in men with a “non-suspicious” total PSA ange below 4 NG/ML? — Results of a multicenter trial (2003) (0)
- 16 Infektionskrankheiten (II) (2016) (0)
- Mikro-RNA in der Uroonkologie (2009) (0)
- 24 Laborwerte/Nährstoffzufuhr (2016) (0)
- Lothar Jäger – zum 75. Geburtstag (2009) (0)
- Biomonitoring — Eine Methode der Umweltanalytik (1996) (0)
- Biomarker des Knochenstoffwechsels in Serum und Urin bei ossären Metastasen (2014) (0)
- Means and methods for diagnosing prostate (2010) (0)
- 1020 DIFFERENTIAL CLAUDIN-1 EXPRESSION PATTERN IN PAPILLARY AND CLEAR CELL RENAL CELL CARCINOMA IS ASSOCIATED WITH DIVERGENT TUMOUR BEHAVIOUR AND SURVIVAL (2009) (0)
- 227 Circulating free genomic and mitochondrial DNA fragments and their diagnostic and prognostic potential in clear cell renal cell carcinoma patients (2016) (0)
- Prostate Cancer Screening. Ian M. Thompson, Martin I. Resnick, and Eric A. Klein, eds. Totowa, NJ: Humana Press, 2001, 317 pp. (plus one compact disc), $99.50, hardcover. ISBN 0-89603-901-3. (2002) (0)
- Festlegung der optimalen und maximalen Dauerleistung aufgrund des Atemäquivalentes (1973) (0)
- Survivin and ERCC-1 expression as prognostic factor for overall survival in patients with muscle-invasive bladder cancer with and without cisplatin-based chemotherapy (2017) (0)
- Neue Serummarker des Prostatakarzinoms und ihr Einsatz in artifiziellen neuronalen Netzwerken (ANN) (2007) (0)
- Quantifizierung von Genexpressionen beim Prostatakarzinom (2007) (0)
- TMPRSS2-ERG fusion transcripts in matched urine and needle rinse material after biopsy for the detection of prostate cancer: really a step forward? (2013) (0)
- 505 INDICATION OF BONE METASTASES IN PROSTATE CANCER PATIENTS AND THEIR SURVIVAL OUTCOME IN CORRELATION TO PLASMA OSTEOPONTIN AND OTHER BONE MARKERS (2007) (0)
- THE MATRIX-METALLOPROTEINASE INHIBITOR RECK AFFECTS PROSTATE CANCER PROGRESSION (2008) (0)
- Abstract 1772: Calcium activated nucleotidase 1 (CANT1) promotes progression of prostate carcinomas (2010) (0)
- Referenzbereiche der löslichen Adhäsionsmoleküle CD44 (Standard), CD44(v5) und CD44(v6) im Serum gesunder Erwachsener (1995) (0)
- Identification of a Pharmacologically Active Metabolite of Mycophenolic Acid in Plasma of Transplant Recipi- Ents Treated with Mycophenolate Mofetil, Ekkehard (0)
- Komplexiertes oder freies prostataspezifisches Antigen: welche Komponente sollte zur Differenzierung zwischen benigner Prostatahyperplasie und Prostatakarzinom bestimmt werden?. Complexed or Free Prostate Specific Antigen: Which Component Should be Determined to Improve the Differentiation between B (1999) (0)
- Electronic-Shopping - Die Zukunft des Versandhandels? (2000) (0)
- (cid:1) -Trace Protein, Cystatin C, (cid:1) 2 -Microglobulin, and Creatinine Compared for Detecting Impaired Glomerular Filtration Rates in Children (2002) (0)
- Pitfalls in the determination of circulating matrix metalloproteinases and their inhibitors by disregarding fundamental laboratory principles. (2013) (0)
- Dicke Bilder durch dünne Leitungen. Konzepte und Algorithmen der Bilddatenkompression (2000) (0)
- Konkretisierung und empirische Fundierung des Modells zur Beschreibung und Erklärung von Fließsystemen am Beispiel der Beschaffungslogistik in der Automobilindustrie (1999) (0)
- IMMUNO HISTOCHEMICAL EXPRESSION OF CLAUDIN-1 AS A PROGNOSTIC MARKER FOR PATIENT SURVIVAL IN RENAL CELL CARCINOMA (2008) (0)
- Improved selection for prostate biopsy (2017) (0)
- 209 METABOLITE PROFILING AS TOOL FOR THE IDENTIFICATION OF DIFFERENTIATING AND PROGNOSTIC MARKERS OF PROSTATE CARCINOMA (2013) (0)
- Zentralisierung um jeden Preis (2010) (0)
- 24. Deutscher Physikertag in Berlin vom 29. Sept. bis 3. Okt. 1959/Österreichische Physikertagung in Innsbruck vom 6. bis 8. Oktober 1959/550-Jahrfeier der Universität Leipzig vom 8. bis 17. Oktober/IUPAC-Symposium über Makromoleküle in Wiesbaden vom 12. (1959) (0)
- 625 COMPLICATIONS, URINARY CONTINENCE, AND ONCOLOGICAL OUTCOME (2007) (0)
- Wirkung von Penicillin G auf wachsende Zellen von Escherichia coli B in H2O- und D2O-Komplettmedien (2004) (0)
- 984 FAULTY RISK PREDICTION OF PROSTATE CANCER BY NOMOGRAMS WITHOUT CONSIDERING PSA INTER-ASSAY VARIABILITY (2010) (0)
- Neue Serummarker zur Diagnostik von Knochenmetastasen beim Prostatakarzinom (2007) (0)
- CD59 expression in prostate cancer: a new marker of disease progression? (2004) (0)
- Re: Free and complexed prostate specific antigen in the differentiation of benign prostatic hyperplasia and prostate cancer: studies in serum and plasma samples. (1999) (0)
- Down-Regulationof theHumanKallikreinGene 5 ( KLK 5 ) in ProstateCancerTissues (2002) (0)
- Pdt of Prostatecancer Pdt of Prostatecancer Analysis of Tumor Spillage during Radical Prostatectomy Using Rt-pcr of Prostate Specific Antigen. Expression of Vascular Endothelial Growth Factor and Its Receptors in the Rat Ventral Prostate and Dunning (0)
- 16 Infektionskrankheiten (I) (2016) (0)
- Differential Expressionof theHumanKallikreinGene 14 ( KLK 14 ) inNormalandCancerous ProstaticTissues (2003) (0)
- [Biochemical research in kidney transplantation]. (1989) (0)
- [Na K ATPase activity in rat kidneys following storage at 4 degrees C in various kidney preservative solutions]. (1990) (0)
- [D-glucaric acid excretion in kidney transplant patients as an indicator of microsomal enzyme capacity]. (1982) (0)
- Nachruf Lothar Jäger (13. Februar 1934 – 4. Juli 2020) (2020) (0)
- Prostate volume and its influence on clinical parameters in prostate cancer detection (2023) (0)
- Wirkung von Fluticason auf die Aktivität von Matrix-Metalloproteinase 2 (MMP2) aus Bronchialmyozyten (2005) (0)
- [Excretion of beta-N-acetylglucosaminidase in urine of patients with kidney transplants and workers exposed to cadmium]. (1991) (0)
This paper list is powered by the following services:
What Schools Are Affiliated With Klaus Jung?
Klaus Jung is affiliated with the following schools:
